These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 18239303)

  • 1. Process development and large-scale synthesis of NK1 antagonist.
    Araya I; Kanazawa S; Akita H
    Chem Pharm Bull (Tokyo); 2008 Feb; 56(2):176-80. PubMed ID: 18239303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem; 2005 Oct; 13(20):5717-32. PubMed ID: 15993086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Bicyclic Pyrimidine Derivative (KRP-103), a Novel Selective Tachykinin NK1 Receptor Antagonist, on Bladder Function in Guinea Pigs.
    Tanioka A; Deguchi T
    Drug Res (Stuttg); 2017 May; 67(5):302-307. PubMed ID: 28268237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1485-8. PubMed ID: 15713412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1479-84. PubMed ID: 15713411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.
    Natsugari H; Ikeura Y; Kamo I; Ishimaru T; Ishichi Y; Fujishima A; Tanaka T; Kasahara F; Kawada M; Doi T
    J Med Chem; 1999 Sep; 42(19):3982-93. PubMed ID: 10508446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
    Di Fabio R; Alvaro G; Griffante C; Pizzi DA; Donati D; Mattioli M; Cimarosti Z; Guercio G; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
    J Med Chem; 2011 Feb; 54(4):1071-9. PubMed ID: 21229983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways.
    Kassick AJ; Jiang J; Bunda J; Wilson D; Bao J; Lu H; Lin P; Ball RG; Doss GA; Tong X; Tsao KL; Wang H; Chicchi G; Karanam B; Tschirret-Guth R; Samuel K; Hora DF; Kumar S; Madeira M; Eng W; Hargreaves R; Purcell M; Gantert L; Cook J; DeVita RJ; Mills SG
    J Med Chem; 2013 Jul; 56(14):5940-8. PubMed ID: 23808489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
    Duffy RA; Varty GB; Morgan CA; Lachowicz JE
    J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A practical preparation of methyl 2-methoxy-6-methylaminopyridine-3-carboxylate from 2,6-dichloro-3-trifluoromethylpyridine.
    Horikawa T; Hirokawa Y; Kato S
    Chem Pharm Bull (Tokyo); 2001 Dec; 49(12):1621-7. PubMed ID: 11767084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the synthesis of cyclic pentapeptides as LHRH antagonists and the factors that influence cyclization yield.
    Gao XM; Ye YH; Bernd M; Kutscher B
    J Pept Sci; 2002 Aug; 8(8):418-30. PubMed ID: 12212805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A concise, efficient and versatile synthesis of amino-substituted benzo[b]pyrimido[5,4-f]azepines: synthesis and spectroscopic characterization, together with the molecular and supramolecular structures of three products and one intermediate.
    Acosta Quintero LM; Burgos I; Palma A; Cobo J; Glidewell C
    Acta Crystallogr C Struct Chem; 2018 Mar; 74(Pt 3):312-320. PubMed ID: 29504560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist.
    Gao T; Liu Y; Ji Y; Wu X; Xu J
    J Pharm Biomed Anal; 2012 Jul; 66():381-6. PubMed ID: 22516679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists.
    Ohnmacht CJ; Albert JS; Bernstein PR; Rumsey WL; Masek BB; Dembofsky BT; Koether GM; Andisik DW; Aharony D
    Bioorg Med Chem; 2004 May; 12(10):2653-69. PubMed ID: 15110847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gas chromatographic/mass spectrometric analysis of oxo and chain-shortened leukotriene B4 metabolites. Leukotriene B4 metabolism in Ito cells.
    Wheelan P; Murphy RC; Simon FR
    J Mass Spectrom; 1996 Mar; 31(3):236-46. PubMed ID: 8799275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
    Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
    Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An efficient transformation of cyclic ene-carbamates into omega-(N-formylamino)carboxylic acids by ruthenium tetroxide oxidation.
    Kaname M; Yoshifuji S; Sashida H
    Chem Pharm Bull (Tokyo); 2008 Sep; 56(9):1310-3. PubMed ID: 18758107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral activity of a new NK1 receptor antagonist TAK-637 in the gastrointestinal tract.
    Venkova K; Sutkowski-Markmann DM; Greenwood-Van Meerveld B
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1046-52. PubMed ID: 11861814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of metabolites of a NK1 receptor antagonist, CJ-11,972, in human liver microsomes and recombinant human CYP isoforms by liquid chromatography/tandem mass spectrometry.
    Prakash C; Lin J; Colizza K; Miao Z
    Rapid Commun Mass Spectrom; 2007; 21(17):2822-32. PubMed ID: 17661339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
    Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
    Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.